Spring sale! Get NewsNow Essentials at just £2.99 a month (40% OFF!). Faster, slicker, customisable & ads free!Spring sale! Get NewsNow Essentials at just £2.99 a month (40% OFF!). Go ads free today!Spring sale! Upgrade now at £2.99/m (40% OFF!)

Home
Hot Topics
UK
World
Gaza
Ukraine
Iran
Climate Crisis
Business
Football
Sport
Entertainment
Tech
Science

Celltrion
Biotech
Moderna
Topics

Advertisement

Celltrion

Share

Top Latest Popular

🐣 SPRING SALE! Go ads free in 2026, with NewsNow Essentials for just £2.99 a month!

🐣 SPRING SALE! Stay informed ads free in 2026, with NewsNow Essentials for just £2.99 a month! Upgrade today!

Friday

Celltrion’s Zymfentra sees 185% surge in US prescriptions The Korea Herald 03:36 Fri, 08 May

Thursday

Celltrion highlights new CT-P13 SC data at DDW 2026, reinforcing IBD treatment potential Korea Biomedical Review 05:34 Thu, 07 May

Wednesday

Celltrion posts record first-quarter results Miami Herald 16:04 Wed, 06 May

Advertisement

Advertisement

Celltrion Q1 Net Income Rises RTT News 05:32 Wed, 06 May

Celltrion’s profit doubles as biosimilar demand drives record revenue The Korea Times 04:08 Wed, 06 May

Celltrion’s Q1 operating profit more than doubles on biosimilar growth Korea Biomedical Review 03:35 Wed, 06 May

Celltrion posts record Q1 earnings on strong biosimilar sales The Korea Herald 03:26 Wed, 06 May

Celltrion Q1 net income up over 3-fold on high-margin products Yonhap News Agency 01:47 Wed, 06 May

In the last month

Celltrion files Herceptin biosimilar SC formulation with EMA Korea Biomedical Review 09:03 Thu, 30 Apr

Celltrion enters Japanese market for arthritis treatments with new biosimilar The Korea Times 07:27 Tue, 28 Apr

Celltrion launches Avtozma in Japan, entering tocilizumab market as first mover Korea Biomedical Review 05:14 Tue, 28 Apr

Celltrion begins dosing for 3 ADC cancer candidates Korea Biomedical Review 06:30 Thu, 23 Apr

Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW) PR Newswire (Press Release) 13:07 Tue, 21 Apr

Celltrion obtains Japanese approval for Steqeyma IV formulation Korea Biomedical Review 09:09 Tue, 21 Apr

Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (trastuzumab-dttb)... JD Supra 16:45 Fri, 17 Apr

Spotlight On: Biosimilar Litigations - April 2026 JD Supra 21:23 Thu, 16 Apr

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx) - April... JD Supra 20:11 Thu, 16 Apr

Celltrion gains ground in Europe as prescriptions rise across portfolio Korea Biomedical Review 05:22 Thu, 16 Apr

Advertisement

Celltrion becomes only Korean biotech firm in S&P Global's top 1% ESG companies Korea Biomedical Review 05:22 Wed, 15 Apr

Celltrion named Top 1% in S&P Global ESG ranking The Korea Herald 03:18 Wed, 15 Apr

Celltrion completes largest-ever share cancellation in Korean biotech Korea Biomedical Review 05:54 Tue, 14 Apr

Advertisement

Advertisement

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.

NewsNow

Our Sites

NewsNow Nigeria

NewsNow România

NewsNow Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Biotech Biotech
Back to Industry Sectors Biotech
- GM Food GM Food
- AbbVie AbbVie
- Amgen Amgen
- Biogen Biogen
- BioNTech BioNTech
- Celltrion Celltrion
- Genentech Genentech
- Gilead Sciences
- Illumina Illumina
- Moderna Moderna